Close

Protagonist Therapeutics to Participate in the JMP Securities Life Sciences Conference May 11, 2023 04:05PM
Protagonist Therapeutics to Participate in the JMP Securities Hematology and Oncology Summit Dec 1, 2022 07:05AM
UPDATE: JMP Securities Resumes Protagonist Therapeutics (PTGX) at Market Outperform Aug 25, 2022 04:53AM
Protagonist Therapeutics to Present at the JMP Securities Hematology and Oncology Summit Dec 3, 2021 07:00AM
Protagonist Therapeutics, Inc. Announces Closing of $132.2 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares Jun 18, 2021 04:05PM


Jun 16, 2021 06:18AM Protagonist Therapeutics (PTGX) Announces Pricing of $115 Million Upsized Public Offering of Common Stock
Jun 15, 2021 09:07PM Protagonist Therapeutics Announces Pricing of $115 Million Upsized Public Offering of Common Stock
Jun 14, 2021 05:01PM Protagonist Therapeutics (PTGX) Announces Proposed $100M Public Offering of Common Stock
Jun 14, 2021 05:00PM Protagonist Therapeutics Announces Proposed Public Offering of Common Stock
Jun 11, 2021 01:42PM Protagonist Therapeutics (PTGX) PT Raised to $55 at JMP Securities, Following Clinical Business Update
May 24, 2021 05:05AM UPDATE: JMP Securities Starts Protagonist Therapeutics (PTGX) at Market Outperform
Jun 6, 2018 07:00AM Protagonist Therapeutics to Present at the 2018 JMP Securities Life Sciences Conference